About This Fund
Forbion Growth Opportunities Fund II is a €600 million life sciences growth fund managed by Forbion, the Netherlands-based specialist venture capital firm headquartered in Naarden with offices in Munich and Boston. The fund reached its hard cap and completed its final close in April 2023 as part of a simultaneous €1.35 billion raise alongside Forbion Ventures Fund VI. New institutional investors joining the fund included Amundi and Legal & General Capital, complementing existing backers Dutch pension funds PME and PMT, Pantheon Ventures, and Eli Lilly and Company.
The fund focuses on later-stage European biopharmaceutical companies developing novel therapies in areas of significant unmet medical need, with selective exposure to North American crossover opportunities. Forbion leads investments of up to €70 million per company, taking board seats and providing active support through clinical milestones and liquidity events. Primary investment areas span oncology, rare diseases, immunology, and other clinical-stage therapeutic categories. As of its final close in April 2023, the fund had already made four portfolio investments, demonstrating rapid capital deployment aligned with Forbion's established deal pipeline.
Forbion Growth Opportunities Fund II is the second vehicle in the Growth Opportunities franchise, following Fund I (€360 million, 2021). The strategy reflects Forbion's systematic approach to late-stage biopharma investing, leveraging scientific expertise, an extensive network in European academic institutions, and privileged access to global crossover investors. The institutional LP base spanning pan-European asset managers, strategic pharma investors, fund-of-funds, and pension allocators underscores strong demand for European life sciences growth equity.